PRESS RELEASE
Oct 26, 2026
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
Oct 22, 2026
MindWalk Holdings Corp. Announces Leadership Update
Oct 21, 2026
AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
Oct 21, 2026
MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
Oct 14, 2026
AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
Oct 14, 2026
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
Oct 06, 2026
Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context
Oct 06, 2026
MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
Oct 01, 2026
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Oct 01, 2026
MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director